Journal Home
Search for

Volume 20, Issue 2, Pages 110-116 (February 2010)


View previous. 6 of 12 View next.

Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: The DEMAND Study

M.C.E. RossiaCorresponding Author Informationemail address, A. Nicoluccia, F. Pellegrinia, M. Comaschib, A. Cerielloc, D. Cucinottad, C. Giordae, B. Pomilia, U. Valentinif, G. Vespasianig, S. De Cosmoh

Received 22 September 2008; received in revised form 4 February 2009; accepted 27 February 2009. published online 18 May 2009.

Abstract 

Background and aims

Obesity is a potential risk factor for renal disease in non-diabetic subjects. It remains unclear whether this also applies to diabetic patients. We investigated whether obesity predicted changes in albumin excretion rate in individuals with type 2 diabetes.

Methods and results

Fifty Italian diabetes outpatient clinics enrolled a random sample of 1289 patients. A morning spot urine sample was collected to determine urinary albumin/creatinine ratio (ACR) at baseline and after 1 year from the study initiation. Progression of albumin excretion was defined as a doubling in ACR, while regression was defined as a 50% reduction. Multivariate logistic regression analyses were used to evaluate correlates of these outcomes. Data are expressed as odds ratios (OR) with 95% confidence intervals (CI).

The risk of progression increased by 7% (OR=1.07; 95%CI 1.00–1.15) for every 5-cm increase in waist circumference measured at baseline, and by 17% (OR=1.17; 95%CI 1.03–1.33) for every one-unit increase in BMI during follow-up. The likelihood of regression was not independently associated with any of the variables investigated. The effect of obesity on progression of ACR was independent of metabolic control, blood pressure, treatment, and baseline level of albumin excretion.

Conclusions

We found a tight link between obesity and changes in albumin excretion in diabetic subjects, suggesting potential benefits of interventions on body weight on end-organ renal damage.

a Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, Via Nazionale, 66030 S. Maria Imbaro, CH, Italy

b Department of Internal Medicine, La Colletta Hospital, Genoa, Italy

c Warwick Medical School, University of Warwick, Coventry, UK

d Department of Internal Medicine, Policlinico Universitario, Messina, Italy

e Metabolism and Diabetes Unit ASL TO5, Chieri (TO), Italy

f Diabetologic Unit, Spedali Civili di Brescia, Brescia, Italy

g Diabetes and Metabolism Unit, Madonna del Soccorso Hospital, San Benedetto del Tronto, AP, Italy

h Unit of Endocrinology, Casa Sollievo della Sofferenza, San Giovanni Rotondo, FG, Italy

Corresponding Author InformationCorresponding author. Tel.: +39 0872 570266; fax: +39 0872 570263.

PII: S0939-4753(09)00045-3

doi:10.1016/j.numecd.2009.02.013


View previous. 6 of 12 View next.